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The 'protein only' hypothesis postulates that the prion,
the agent causing transmissible spongiform encephalo-
pathies, is PrPSC, an isoform of the host protein PrPC.
Protease treatment of prion preparations cleaves off
-60 N-terminal residues of PrPSC but does not abrogate
infectivity. Disruption of the PrP gene in the mouse
abolishes susceptibility to scrapie and prion replication.
We have introduced into PrP knockout mice transgenes
encoding wild-type PrP or PrP lacking 26 or 49 amino-
proximal amino acids which are protease susceptible
in PrPSc. Inoculation with prions led to fatal disease,
prion propagation and accumulation of PrPsc in mice
expressing both wild-type and truncated PrPs. Within
the framework of the 'protein only' hypothesis, this
means that the amino-proximal segment of PrPC is not
required either for its susceptibility to conversion into
the pathogenic, infectious form of PrP or for the
generation of PrPSc.
Keywords: PrP complementation/PrP expression vectors/
PrP knockout mice/PrP mutations/reverse genetics
Introduction
A wealth of data supports the 'protein only' hypothesis
(Griffith, 1967) which proposes that the prion, the agent
responsible for transmissible spongiform encephalopathies
(TSEs), is a modified, pathogenic form of a constitutive
host protein and that it multiplies by converting the normal
form into a likeness of itself (Prusiner, 1991). The host
protein, PrPC, and its modified form, PrPsc, have been
isolated; both are encoded by the same gene (Basler et al.,
1986) and are believed to be conformational isomers. Co-
purification experiments demonstrate physical linkage of
infectivity with PrPsc (Bolton et al., 1982; Gabizon et al.,
1988). A scrapie-specific nucleic acid has never been
detected (Kellings et al., 1993), arguing against the virus
(Diringer et al., 1994) and virino (Dickinson and Outram,
1988) hypotheses. Because the ratio of infectious units to
PrPsc molecules is only ~ 1:100 000 (Bolton et al., 1991),
the structure of the prion protein (PrP) molecule actually
associated with infectivity cannot be inferred definitively.
For this reason, and because specific infectivity can vary
considerably, the PrP species responsible for infectivity is
presently better designated as PrP* (Weissmann, 1991); it
may or may not be identical with PrPsc, the major species
that has been characterized chemically and physico-
chemically. If it is identical, the low specific activity could
be due to low efficiency of infection or to the infectious unit
being an aggregate of a large number of PrPsc molecules.
Genetic evidence linking PrP to prion diseases is com-
pelling. Ablation of the PrP gene renders mice resistant
to experimental scrapie and precludes replication of the
infectious agent; reintroduction of PrP transgenes restores
susceptibility to scrapie (Bueler et al., 1993; Sailer et al.,
1994). The so-called species barrier, which hinders prion
transmission from one host species to another, is overcome
by introducing PrP transgenes from the prion donor to the
recipient (Prusineretal., 1990; Bueleretal., 1993). Remark-
ably, all familial cases of TSE in man are probably linked
to one of many possible mutations in the PrP gene (Baker
and Ridley, 1992); these mutations are thought to facilitate
occasional spontaneous conversion of PrPC to PrPsc (or
PrP*), which is then followed by the autocatalytic process.
PrPc and PrPsc are chemically indistinguishable (Stahl
et al., 1993) but differ in their secondary structure and
physico-chemical properties. PrPC has a very low and PrPsc
a high content of ,8-pleated sheet structure (Caughey et al.,
1991; Pan et al., 1993). Under conditions where PrPc is
readily degraded by proteinase K, PrPsc is partially resistant.
About 60 N-terminal residues are cleaved off and the
remainder ofthe molecule is quite stable. Under these condi-
tions of protease treatment, prion preparations retain full
infectivity. It has been shown earlier, by introducing a trun-
cated version of the PrP gene into scrapie-infected N2A
neuroblastoma cells, that PrPc devoid of 66 N-terminal
amino acids can still give rise to PrPsc; however, it was
not determined whether infectivity was associated with the
truncated PrPsc molecule (Rogers et al., 1993).
We now show that introduction of truncated PrP trans-
genes encoding PrPc devoid of as many as 49 amino-
proximal amino acids into PrP knockout mice restores sus-
ceptibility to scrapie, allows prion propagation and leads to
accumulation of PrPsc. Within the framework ofthe 'protein
only' hypothesis, this means that the amino-proximal seg-
ment of PrPc is required neither for conversion into the
pathogenic, infectious form of PrP nor for the generation
of PrPsc.
Results
Introduction of transgenes encoding wild-type
murine PrP into Prnp0"0 mice restores
susceptibility to mouse prions
We have shown earlier that Pmp010 mice are resistant to
experimental scrapie and do not propagate the infectious
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Fig. 1. Wild-type and mutant PrP-encoding genes. (A) Maps of constructs encoding wild-type PrP. Cos6. 11, a cosmid-derived clone comprising three
exons (El, E2 and E3), two introns (I1 and 12), 6 kb of 5'- and 17 kb of 3'-flanking regions; phgPrP, as before, but lacking intron 2 and with only
2.2 kb of 3-flanking region; pPrPcDNA, as phgPrP, but lacking both introns. (B) Wild-type and mutant constructs derived from phgPrP. The boxes
represent the part of the transcription unit comprised of exons 2 and 3. Open boxes, 5'- and 3'-non-coding; hatched, 5' and 3' signal sequences;
lightly stippled, coding sequence of mature PrP; dark stippled boxes and underlined sequence, octa repeats; horizontal black bar, protease-sensitive in
PrPSC; arrowhead, beginning of the sequence resistant to protease in PrPSC; *, deletion breakpoints. (C) Flowsheet for the construction phgPrP and
pPrPcDNA; details are given in Materials and methods. (D) Detailed view of phgPrP showing the origin of the various segments and the primers
(arrows) used in various PCRs. Hatched box, 5'-flanking region; light stippled, non-coding regions; heavy stippled, ORF; heavy lines, intron or 3'-
flanking regions.
agent (Bueler et al., 1993; Sailer et al., 1994). Moreover,
breeding multiple hamster Prnp transgenes into Pmp010
mice rendered the latter highly susceptible to hamster
prions but much less so to mouse prions.
We now undertook to introduce genes encoding wild-
type and mutated murine PrP into Pmpolo mice by
transgenesis. For this purpose, we examined several PrP-
encoding constructs for their efficacy in restoring suscepti-
bility to scrapie. Wild-type mice containing multiple Prnp
transgenes have been generated previously by injecting
40 kb cosmid DNA containing genomic Prnp into one-
cell embryos of wild-type mice, and efficient expression
of PrP was achieved (Scott et al., 1989; Hsiao et al., 1990).
The mouse PrP gene contains an upstream intron of
2 kb and a downstream intron of 6-12 kb (Westaway
et al., 1994a). In order to facilitate mutagenesis, we
generated a PrP-encoding construct from which the large
intron ('half-genomic construct' or phgPrP) or both introns
('cDNA construct' or pPrPcDNA) were deleted and which
contained 5.5 kb of 5'- and 2 kb of 3'-flanking sequence
(Figure lA). These constructs, as well as the Prnp-
containing cosmid DNA (cosmid cos6.IflnJ4; Westaway
et al., 1991) were introduced into Prnp010 or Prnp0l+ mice
by nuclear injection. Founders were identified and bred
to yield Prnpolo lines homozygous or heterozygous for the
PrP-encoding transgene array.
PrP expression in the brain was monitored by Northern
analysis (Table I). In all but one of the six lines carrying
half-genomic Prnp transgenes tested, PrP was expressed.
In contrast, the cDNA construct, in all eight lines tested,
even in those (tgb9/+, tgb24/+) with very high transgene
copy numbers (> 150 copies), showed no detectable levels
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Table I. Characteristics of mouse lines with various PrP genotypesa
Line PrP-encoding Gene copy PrP RNAC PrP Inoculum Days to Days to terminal No. of animals
gene No.b proteind symptoms disease inoculated
Prnp+l+ Prnpa 2 1 1 RML 131 + 9 166 + 8 9
Prnp(0+ prnpa 1 0.5 0.5 RML 290 + 33 415 + 30 19/15
tgal9/+ hgPrnp" 30 no data 3-4 RML 87 + 13 100 + 17 13
tga2O/+ hgPrnpa 30 1.2 6-7 RML 64 + 9 68 + 10 15
tga2O/tga2O hgPrnpa 60 no data 10 RML 60 + 4 62 + 4 6
tgc35/+ Prnpb(cosrnid) 40 no data 4-5 RML 121 + 10 130 + 7 8
tgb24/+ PrPcDNA 150 <0.5 not detected none - - none
tgel9h/+ PrPANco 150 1.8 3-4 RML 67 + 17 72 + 16 7
tgel91/+ PrPANco 15 1 1.5-2.5 RML 101 + 5 104 + 9 4
tgdll/+ PrPAN-term 30 2.7 6 RML 97 + 9 103 11 6
tgdl2/+ PrPAN-term 40 3.9 10-12 RML 86 11 89 + 12 8
aPrnp(l+, from Bueler et al. (1994); tga2O/tga20, partly from Brandner et al. (1995).
bRelative to wild-type; determined by quantitative PCR.
cRelative to wild-type; determined by quantitative Northern analysis.
dRelative to wild-type; determined by densitometric analysis of Western blots.
of PrP protein in the brain and only very weak (tgb24/+)
or no expression of PrP RNA (data not shown). The one
line of cosmid transgenic mice examined showed efficient
PrP expression, as expected from previous work
(Westaway et al., 1991). These results, in agreement with
earlier data (Scott et al., 1989), show that the presence of
at least one intron is essential for the efficient expression
of a PrP-encoding transgene under the control of its own
promoter. A requirement of introns for efficient (Brinster
et al., 1988) and/or tissue-specific (Lozano and Levine,
1991) expression of some transgenes has been described
previously.
Two half-genomic (tgal9/+; tga2O/+) mouse lines and
one cosmid mouse line (tgc35/+), all with similar gene
copy numbers of -30-40, were analyzed in more detail.
As shown in Figure 2 and Table I, all three lines over-
expressed PrP in the brain at levels ranging from ~3- to
4-fold and 4- to 5-fold (tgal9/+ and tgc35/+ respectively)
to 6- to 7-fold (tga2O/+) of those observed in wild-type
P)np+/+ animals. The distribution of PrP transcripts in
the brains of the two half-genomic and the cosmid lines
was analyzed by in situ hybridization of brain sections
with a PrP antisense riboprobe (Figure 3). Overall levels
of PrP RNA were higher in the brains of transgenic than
in those of wild-type animals. The expression patterns
were similar in transgenic and wild-type mice, with highest
PrP RNA levels in the hippocampus (Figure 3A, C and
E) and the cerebellum (Figure 3B, D and F). In some
areas, like the molecular layer of the cerebellum, PrP
RNA-positive cells were clearly visible in transgenic but
only very faintly in wild-type mice, supporting the notion
that expression of PrP RNA was generally increased.
Interestingly, however, PrP RNA was not detected in the
Purkinje cells of animals carrying half-genomic transgenes
(tga19, Figure 3F; tga2O, not shown), while it was abundant
in Purkinje cells of wild-type and cosmid transgenic mice
(Figure 3B and D). This suggests that one or more control
elements responsible for the specific expression of PrP in
Purkinje cells are absent from the half-genomic construct.
Some animals containing the cosmid transgene (tgc35/
+; tgc35/c35, Prnp allele b) gradually developed paresis
of their hind-limbs as early as 4-6 months after birth.
Similar symptoms in mice overexpressing this as well as
other types of Prnp cosmid transgenes have been described
earlier (Westaway et al., 1994b). Animals expressing half-
genomic PrP-A, at even higher levels in the brain (tga2O/+,
tga20/tga20), revealed no obvious pathological phenotype.
This difference could be due to the different allelic nature
of the two transgenes (Carlson et al., 1988), to differences
in expression patterns or to overexpression of an unidenti-
fied gene product encoded by sequences present in the
cosmid but not in the half-genomic construct. Because
these symptoms were found in several independent PrP
cosmid transgenic mouse lines, it seems unlikely that they
were due to position effects of the transgene integration.
To determine whether the half-genomic construct could
restore susceptibility to scrapie, mice hemizygous for the
half-genomic tga2O/+ and tgal9/+ transgene insertion
were inoculated with mouse prions. As positive controls,
tgc35/+ animals hemizygous for the cosmid transgene
array and Prnp+'l mice of comparable genetic background
to the Prnp°/° mice used for the generation of the transgenic
lines (offspring of C57/Bl6X 129/SV crosses; Bueler et al.,
1992) were inoculated similarly. Negative controls were
Pmp0/0 mice inoculated with prions and mock-inoculated
transgenic animals. Results are compiled in Figure 4. The
negative control groups remained free of scrapie during
the time of observation, for up to 500-600 days post-
inoculation (data not shown). One mock-inoculated tga20/
+ animal died 538 days p.i., after showing kyphosis and
tremor, symptoms which occur in scrapie-infected but
occasionally also in uninoculated aging mice; it was not
analyzed further.
Scrapie-inoculated mice expressing the half-genomic
construct or the cosmid displayed typical scrapie symp-
toms, such as hind-limb paresis, foot-clasp reflex,
kyphosis, ataxia, disorientation and minced gait. Incuba-
tion times to the occurrence of first symptoms as well as
to the terminal state (Table I) were shorter than in the
wild-type control group, namely 68 ± 10 days for
tga2O/+ and 100 ± 17 days for tgal9/+ (the two lines
expressing the half-genomic transgene) and 130 ± 7 days
for tgc35/+ (the line canfying the cosmid), as compared
with 166 ± 8 days for wild-type mice. In addition, the
duration of clinical disease was greatly decreased in the
transgenic animals: in the tga2O/+ line, terminal disease
occurred as early as 4 + 2 days after the observation of
the first symptoms, as compared with 35 + 12 days in
1257
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Fig. 2. PrP mRNA and protein levels in brains of mice transgenic for wild-type and mutant PrP-encoding genes. (A) Northern blots were performed
on 10 ,ug of total RNA as described in Materials and methods. PrP: the labeled probe corresponded to a region of the Prnp gene deleted in Prnp010
mice. Actin: the filter was stripped and rehybridized with a chicken P-actin cDNA probe. (B) Western blots of total mouse brain homogenates. One
half mouse brain was homogenized in 1.35 ml of 0.5% SDS, 50 mM Tris-HCI (pH 6.8), 5 mM EDTA, 0.25 M PMSF, and 200 ,l of lysate was
mixed with 500 gl of SDS loading buffer (Laemmli, 1970) without reducing agent. Samples (20-40 gl) were electrophoresed through a 12.5%
polyacrylamide gel. Western blotting was carried out as described (Bueler et al., 1994) using antiserum R073 (lanes 1-6), 1B3 (lanes 7-14) or
R3430 (lanes 15-21) and developed with the ECL system. All mice were hemizygous for the mutant alleles and Prnp010, except for the wild-type
(wt).
the wild-type group. Furthermore, shorter incubation times
correlated with higher expression levels of PrPc when
lines tgal9/+ and tga20/+ were compared, consistent
with an inverse correlation between these two parameters,
as suggested earlier (Scott et al., 1989; Bueler et al., 1994).
Because tga2O mice showed such a short incubation
time compared with the usual wild-type indicator mice,
we explored the possibility of using them for prion titration
by the incubation time assay (Prusiner et al., 1982). The
titer of a prion preparation was determined by end point
titration in tga2O mice (Reed and Muench, 1938). Table
II shows the relationship between incubation period and
inoculated dose; the data were used to determine the
parameters of the equation: loglO(titerXdilution) = a-b
(incubation time).
Generation and characterization of mice
transgenic for mutant PrP genes
The observation that moderate treatment of preparations
of scrapie agent with proteinase K removes amino acids
23-80 of mouse PrPSc (Hope et al., 1988) without abrogat-
ing infectivity (Neary et al., 1991) suggested that, within
the framework of the 'protein only' hypothesis, the amino-
proximal deletion mutants described above may be func-
tional, provided that the truncated protein is susceptible
to conversion. Moreover, a human PrP allele with a
nonsense mutation in codon 145 has been found in a
patient who suffered from neurodegenerative disease and
had amyloid plaques containing PrP truncated at the
cognate position (Kitamoto et al., 1993). This suggested
that such truncated PrP might also be pathogenic.
Deletion of codons 23-88 of the hamster PrP gene as
well as truncation of the C-terminal codons downstream
of the attachment site for the GPI-anchor did not preclude
conversion of PrPc to PrPSc in scrapie-infected neuroblas-
toma cells (Rogers et al., 1993). However, protease
resistance of PrP is not necessarily linked to scrapie
infectivity (Manuelidis et al., 1987; Xi et al., 1992;
Pocchiari, 1994) and is therefore not a reliable marker for
this property.
In order to define the requirements of PrP for conferring
susceptibility to scrapie and promotion of prion replication,
N- and C-terminal deletion mutants of the PrP gene were
constructed and mice transgenic for these genes were
assessed for susceptibility to scrapie, propagation of prions
and, where appropriate, formation of PrPSC.
Four constructs, based on the half-genomic vector
(Figure 1), were prepared and introduced as transgenes
into Pmp010 mice. The founders were mated to Pmp010
partners and the hemizygous offspring were tested for the
presence and the expression of the PrP transgenes (Table
I, Figure 2). (i) Construct d (pPrPAN-term): the sequence
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Fig. 3. Expression pattern of PrP mRNA in wild-type mice and mice expressing PrP transgenes. Sagittal brain sections of 129/SV(ev)XC57BLJ6-
derived wild-type (A and B), tgc35/+ (Prnp cosmid; C and D), tgal9/+ (hgPrnp; E, F and H) or Prnp0'0 mice (G) were hybridized in situ with
digoxigenin-labeled riboprobes detecting PrP (A-G) or neuron-specific enolase (NSE) RNA (H) as described (Moser et al., 1995). Regions from the
hippocampus (A, C and E) and the cerebellum (B, D, F, G and H) are shown. Note the absence of a PrP RNA-specific signal in Purkinje cells of
tgal9/+ mice (F) even though NSE mRNA can be detected in them in a parallel section (H). Arrows in (F) indicate the positions of Purkinje cell
bodies. Hybridization of PrP probe to Prnpolo (G) mice served as a control for non-specific hybridization signals. Bar, 310 gm in (A), (C) and (E).
encoding amino acids 32-80 (inclusive) was deleted but
the codons for the signal sequence and nine additional
amino acids were retained to ensure correct processing
and localization in the cell. (ii) Construct e (pPrPANco):
the sequence encoding two of the five copies of the octa
repeat PxGGxWGQ (from amino acid 68 to 83 inclusive)
was deleted. (iii) Construct f (pPrP-C-term): the sequence
encoding amino acids 144 (inclusive) to the end was
ablated by fusing codon 143 to the termination codon of
the PrP reading frame. (iv) Construct g (pPrPAN&C-
term): the deletions of constructs d and f were combined,
to give a sequence encoding a mature protein of 73
amino acids.
Most animals carrying the PrPAN-term and PrPANco
transgenes expressed them at both the RNA (Figure 2A)
and protein level (Figure 2B). As expected, the protein
encoded by the PrPAN-term gene showed distinctly higher
mobility than wild-type PrP (Figures 2B and 4), while the
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Fig. 4. Scrapie incubation time of mice expressing different levels of PrP. All mice were derived from 129XC57BL crosses. Prnp01+ mice express
about half the wild-type PrP level. tgal9/+ and tga20/+ are Prnp010 mice containing -30 copies of the hgPrP construct and expressing -3-4 and 6-7
the wild-type level of PrP, respectively. Intracerebral inoculation with mouse scrapie prions was as described (Bueler et al., 1993). Scrapie was
diagnosed if mice showed three or more scrapie-specific symptoms (decreased motor activity, hind-limb paresis, foot-clasp reflex, kyphosis, ataxia,
disorientation, minced gait). The horizontal bars indicate for each mouse the time elapsed from diagnosis until the terminal stage of disease
(immobility or inability to procure food or drink).
Table II. Determination of prion titers in Tga2O mice
Expt Genotype of donor PrP-encoding Time after Dilution of Genotype of Mice Time to Titer' (log LD50
gene inoculation of sample indicator succumbing terminal unit/ml 10%
donor (days) to scrapie disease homogenate)
I tga20/+ hgPrnp 68 10-' tga20/tga20 1/1 69 7.9
tga20/+ hgPrnp 68 10-2 tga20/tga20 3/3 69 + 2 8.9 + 0.2
tga20/+ hgPrnp 68 104 tga20/tga20 3/3 87 5 8.9 0.5
tga2O/+ hgPrnp 68 10 tga20/tga20 4/4 111 + 1 8.3 ± 0.1
tga20/+ hgPrnp 68 l0o- tga2O/tga20 0/4 >274 -
2 Prnp+l+ (CD-1) Prnp -150 10'- tga20/tga20 6/6 61 + 3 7.1 + 0.5
3 tgdi2/+ PrPAN-term 98 10'- tga20/tga20 3/3 78 + 0 6.9
4 tgdi2/+ PrPAN-term 73 10'- tga20/tga2O 3/3 70 + 1 7.8 + 0.1
In all cases, 30 gl of the indicated dilution of a 10% brain homogenate were injected intracerebrally into tga2O/tga2O mice.
aTiters were determined by the incubation time assay (Prusiner et al., 1982), using the relationship y = 14.37-1. lx, where v is log LD50 and x is
incubation time (days) to terminal disease; this relationship was determined from the end point titration of experiment 1.
PrPANco product showed only a slight decrease in mobility
(not detectable in the analyses shown). In contrast, the
mice transgenic for PrPAC-term and PrPAN&C-term
expressed lower levels of PrP transcripts per transgene
copy than wild-type animals and no PrP was detected in
their brains. In some lines carrying 200 or more transgene
copies (tgf6O/+, tgf67/+, tgg46/+), mRNA was present
at levels similar to wild-type animals, and yet it was not
possible to detect PrP in brain extracts using polyclonal
antibodies directed against full-length murine PrP (data
not shown) or a polyclonal antiserum directed against a
peptide present within the expected mutant proteins (Figure
2B, lanes 15-21).
Inoculation of mice carrying mutant PrP
transgenes with prions
Lines of Pmpolo mice carrying a high copy number of
mutated transgenes were chosen for inoculation experi-
ments (Table I). In the case of PrPAN-term, tgdl2/+ mice
with copy numbers of 30-40 in the hemizygous state
expressed truncated PrP at ~10-12 times wild-type. The
lines tgel9h/+ and tgel9l/+, with ~150 and 15 copies of
the PrPANco gene, expressed -3-4 times and twice wild-
type levels of truncated PrP. In the case of lines tgf67/+
and tgg46/+ carrying ~200 copies of PrPAC-term and
PrPAN&C-term respectively, PrP RNA was expressed at
high levels but PrP could not be detected.
Inoculation was with mouse prions as above; the end-
point of the experiment was the appearance of terminal
scrapie symptoms, at which time the animals were sacri-
ficed. As shown in Table I, both N-proximally truncated
transgenes were capable of restoring susceptibility to
scrapie in Prnp010 mice. The two lines expressing PrPANco,
as well as those expressing wild-type PrP, showed incuba-
tion times that appeared to be dependent on PrP levels:
104 ± 9 days and 72 ± 16 days for tgel9l/+ and
tgel9h/+ animals, respectively, values very close to those
of tgal9/+ and tga20/+ animals (100 ± 17 days and
68 ± 10 days respectively (Table I). The two lines
expressing PrPAN-term transgenes, tgdll/+ and tgdl2/+,
displayed incubation times of 103 ± 11 days and 89 ± 12
days, respectively. Both the determination of PrP levels
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Table III. Determination of prion titers in CD-I indicator mice
Expt Genotype of PrP-encoding Time after Dilution of Mice succumbing Time to Estimated titer'
donor gene inoculation of sample to scrapie terminal disease (log LD50 unit/ml
donor (days) 10% homogenate)
1 Prnp+l+ (CD-1) Prnp -150 10-' 6/6 154 + 4 7.7 + 0.6
2 tga2O/+ hgPrnp 68 10'- 4/4 172 + 4 6.1 + 0.6
tga2O/+ hgPrnp 68 10-2 3/3 165 + 6 7.7 + 0.7
3 tgel9h/+ PrPANco 56 lo-' 4/4 166 11 6.6 1
tgel9h/+ PrPANco 56 10-2 4/4 180 10 6.4 + 1
4 tgdi2/+ PrPAN-term 98 10'- 4/4 173 + 0 6.0 + 0.6
tgdl2/+ PrPAN-term 98 10-2 3/3 170 + 7 7.3 + 0.8
In all cases, 30 g1 of the the indicated dilution of a 10% brain homogenate were injected intracerebrally in CD-1 mice.
aTiters were determined by the incubation time assay as described previously (Bueler et al., 1993; see Table II).
and the measurement of incubation times, due to the
small numbers of samples tested in both cases, are only
approximate.
In contrast to the results outlined above, no scrapie symp-
toms were observed in scrapie-inoculated animals trans-
genic for either AC-term or AN&C-term transgenes (>270
days p.i. at the time of writing). This finding is not unexpec-
ted in view of the lack of detectable PrPC in these lines.
Transmission experiments to determine whether prion rep-
lication has occurred in the brains of these animals have
been initiated and have failed to demonstrate the presence
of scrapie infectivity up to 270 days p.i.
Mock-inoculated N-terminal mutant mice remained free
of scrapie symptoms for the entire observation period
(>290 days p.i. at the time of writing) (Table I), except
for one mock-inoculated tgdl2/+ animal which was found
dead at 101 days p.i. after showing kyphosis and foot-
clasp reflex. Histopathology of the poorly preserved brain
was inconclusive.
Determination of scrapie infectivity in brains of
transgenic mice expressing truncated and normal
PrP
We assayed scrapie infectivity on CD-1 wild-type mice,
because the tga2O assay system had not been available
initially. As shown in Table III, titers of brain homogenates
from scrapie-infected, terminal or close to terminal mice
carrying the wild-type hgPrnp transgenes (tga2O), or the
transgenes with the large (tgdl2/+) or small (tgel9h/+)
deletion were all in the range 6-8 log LD50 units/ml of
10% homogenate. These results are supported by similar
data in Table II (the 10-' dilutions used for inoculation
are, however, outside the linear range of the assay and
thus do not yield absolute values).
From these data, it is clear that PrP devoid of amino acids
32-80 is able to restore the capacity of propagating mouse
scrapie prions. Because of the imprecision of the assay and
because incubation times could be prolonged when the PrP
sequence in prion donor and recipient is different (Scott
et al., 1989; Prusiner et al., 1990; Bueler et al., 1993), it is
not possible to conclude whether or not the truncation of
PrP diminished its efficacy to some degree.
Determination of protease-resistant PrP in mice
overexpressing PrP
A pathognomonic feature of prion diseases is the
accumulation of PrPsc, defined by its partial resistance to
limited protease digestion, in scrapie-diseased brains.
Scrapie-sick: - + - + - + - + - + -
1 2 3 4 9 6 7 R Aln1
+ +l +
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t_ ^ * ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~::
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Fig. 5. Western blot analysis for total PrP and PrPs& in brains of mice
transgenic for wild-type and mutant PrP-encoding genes. Samples
from healthy or terminally sick animals were analyzed by Western
blotting as described in Materials and methods using antiserum 1B3.
(A) Mouse brain homogenates were analyzed directly, applying the
equivalent of 0.1 mg of brain tissue. (B) Homogenates were treated
with proteinase K and the solubilized 100 000 g pellet analyzed,
applying the equivalent of 1 mg of brain tissue.
Protease treatment of mouse PrPsc gives rise to PrP27-
30, a truncated form of the mature protein, lacking (in
addition to the signal sequence) 58 N-terminal amino
acids, from Lys23 to Trp8O (Hope et al., 1988). The large
N-terminal mutant gene PrPAN-term was designed to
yield a protein with a similar primary structure to PrP27-
30, except for the retention of the first nine residues of
the mature sequence, Lys23-Trp3I (Figure 1). Therefore,
it was of interest to determine whether scrapie infection
of mice carrying the PrPAN-term transgene would lead
to accumulation of protease-resistant mutant PrP and
whether such molecules would be similarly truncated by
protease treatment.
As shown earlier, PrPsc can be pelleted from detergent-
treated brain homogenates by centrifugation at 100 000 g,
while PrPc remains in the supematant (Meyer et al.,
1986). Brain homogenates were prepared from healthy
and scrapie-sick animals, and samples were subjected to
proteinase K digestion and centrifuged at 100 000 g.
Aliquots of the untreated, total homogenates equivalent
to 0.1 mg of brain tissue and pellet fractions equivalent
to 1 mg of brain tissue were analyzed by immunoblotting
(Figure 5). As reported earlier, the total PrP level of wild-
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type brain increased S5-fold in scrapie-inoculated brains
of terminal animals (Bueler et al., 1994); however, no such
increase was found in the brains of PrP-overexpressing
transgenic animals, either in the case of full-length or of
the AN-term truncated PrP (Figure 5). Unexpectedly, in
PrP-overexpressing scrapie-infected brains, the level of
PrPSC was only about half the wild-type level, in the case
of full-length and only ~25% in the case of truncated
PrP. Thus, in brains of terminally scrapie-sick wild-type
animals, PrPsC was ~50% of total PrP, while in animals
overexpressing PrP this value ranged from 3 to 10%.
The electrophoretic mobility of the amino-proximally
truncated PrP lacking amino acids 32-80 from a tgdl2/+
animal (Figure 5, lanes 7 and 8) is, as expected, greater
than that of wild-type PrP (lanes 1-6); however, proteinase
K-treated PrPSC from wild-type (lanes 10, 12 and 14) and
mutant (lanes 16) have a similar mobility. This suggests
that the primary structure of truncated PrPSC encoded by
PrPAN-tern is similar to that of the protease-resistant
core of normal PrPSc.
Discussion
The finding that mice devoid of PrP were viable and
resistant to scrapie opened up the possibility of carrying
out reverse genetics on the Prnp gene with regard to its
function in prion diseases.
To facilitate the introduction of mutations, we prepared
a mini-Prnp gene ('half genomic Prnp') lacking the large
intron, and determined its capacity to restore expression
of PrP and susceptibility to mouse scrapie. The expression
pattern generated by the mini-Prnp gene in brain differed
slightly from that in wild-type mice or mice transgenic
for the complete Prnp gene introduced as a cosmid clone,
in that PrP mRNA in Purkinje cells was undetectable.
This suggests that the mini-gene lacks a cell-specific
enhancer which could be located in the large intron or in
3'-flanking regions present in the cosmid clone but not in
the truncated construct. Removal of both introns precluded
expression altogether.
Mice carrying - 60 copies of the half-genomic sequence
hgPrnp, such as tga2O/tga2O, expressed ~10 times the
normal PrP level and were very susceptible to scrapie:
the incubation time to terminal disease after inoculation
with ~106 LD50 units of mouse prions was only 61 ± 3
days, as compared with 149 ± 12 days for a standard
wild-type mouse such as CD-1. Because of the short and
reproducible incubation times, we have been using these
mice routinely for titering mouse prion levels (Brandner
et al., 1996).
We obtained transgenic mice which overexpressed PrP
with amino-proximal deletions at levels commensurate
with those of tga2O/+ mice; however, no PrP expression
was found in lines of mice carrying up to ~200 genes
encoding PrP truncated at residue 144, even when the
cognate mRNA was expressed at wild-type level. Because
the C-terminal truncation removed the domain responsible
for anchoring PrP to the cell surface, the protein may
have been secreted and degraded rapidly. It is not clear
why in the case of a patient heterozygous for a Prnp gene
encoding PrP with the analogous deletion (Kitamoto
et al., 1993) the amyloid plaques contained exclusively a
truncated form of PrP. Possibly, the truncated PrP was not
the product of the mutated allele, but a proteolytic fragment
derived from the product of the normal allele. Similarly
truncated fragments have been found in amyloid of
Gerstmann-Straussler-Scheinker disease (GSS) cases and
shown to be derived from full-length PrP, albeit with
missense mutations (Tagliavini et al., 1994).
Curiously, all PrP-overexpressing mice showed lower
absolute levels of PrPSC at the final stages of disease than
wild-type mice, resulting in a ratio of PrPSC to total PrP
of ~0. 1 or less in overexpressing animals and ~0.5 in wild-
type mice. This may come about because accumulation of
PrPSC is a time-dependent process and PrP-overexpressing
mice die early on. In view of our earlier finding that mice
containing a single copy of the Prnp gene have incubation
times of .41 weeks and already have high levels of PrPSC
after 24 weeks, when they are still months away from
showing scrapie symptoms, and of reports that mice
(Hsiao et al., 1994) and humans (Collinge et al., 1995)
succumbing to prion disease may be devoid of detectable
PrPsC, it seems likely that accumulation of high levels of
PrPSC is neither necessary nor sufficient for disease and
death. It should, however, be noted that because the
detection of infectivity is orders of magnitude more
sensitive than that of PrPSC, it is possible that the prion is
associated with a subset of protease-resistant PrP which
we have previously dubbed PrP* (Weissmann, 1991).
The hypothesis that scrapie pathology is due to depletion
of PrPc is not supported by the finding that PrPC-over-
producing mice succumb to disease rapidly, although
relatively little of it is converted to PrPSc.
It has been reported that moderate protease treatment
of scrapie-infected hamster brain homogenates resulted in
little if any decrease of infectivity (McKinley et al., 1983),
and that ~66 amino acids were cleaved off hamster PrPSc
under such conditions. Similar conclusions can be drawn
for mouse PrPSc (Hope et al., 1988; Neary et al., 1991).
If the 'protein only' hypothesis is correct, this means that
the protease-susceptible residues are not required for the
conversion of mature full-length PrPc into PrPSc. Our
experiments comparing mice expressing high levels of
wild-type PrP or PrP lacking residues 32-80 show that
both are susceptible to scrapie and capable of allowing
efficient propagation of the infectious agent. Our data do
not allow us to conclude whether the somewhat longer
incubation times in the case of the shortened PrP molecules
are due to experimental variation or to a moderately lower
efficiency of the shortened molecule in mediating disease.
In order to clarify this point, it will be necessary to replace
the wild-type Prnp gene by the mutated version using
homologous recombination, so as to ensure identical gene
copy numbers and genetic environment. Such experiments
are currently underway.
In any event, it is clear that, by and large, the course
of the disease and the levels of PrPSc attained are very
similar in mice carrying similar copy numbers of truncated
or wild-type PrPC. Within the framework of the 'protein
only' hypothesis, this means that not only is protease-
truncated PrPSc capable of converting PrPc into PrPSc, but
that PrPC devoid of 49 amino-proximal residues is subject
to conversion by full-length PrPSc into a shortened version
of PrPSc with the same susceptibility to protease as its
normal counterpart.
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Materials and methods
DNA constructions
DNA constructions (Figure 1) were carried out according to standard
cloning protocols (Ausubel et al., 1987: Sambrook et al., 1989) using
the following starting DNAs: cos6.I/LNJ-4 (Westaway et al., 1994a);
pNZWBamHI (containing an 8.9 kb segment of the mouse Prnpa gene;
Bueler et al., 1992); pPrPS4 (provided by D.Westaway) consisted of the
7.6 kb XbaI fragment from cos6.I/LNJ-4 comprising Prnp exons 1 and
2 in the XbaI site of pBluescribe; cDNA-NMRI was amplified from
total brain cDNA from NMRI mice using Vent DNA polymerase
(Biolabs), the previously described primer P4 (Bueler et al., 1992)
and primer prc5' (5 'GTCGGATCAGCAGACCGATTCTGGGCGCT3').
Plasmids encoding wild-type and mutant PrPs were constructed as
follows.
pPrPEIilE23RI. The 3 kb Kpnl-BamHI fragment from pPrPS4 (com-
prising exons and 2. intron 1 and part of the promoter) was isolated.
cDNA-NMRI was digested with EcoRI and partially with Kpnl to yield
a 1.3 kb fragment. The two fragments were joined to dephosphorylated
BamtHI- and EcoRI-cleaved pBluescript (Stratagene).
pPRPHG. The NotI-BspEI 5.5 kb fragment from cos6.I/LNJ-4 (compris-
ing part or all of the Prnp promoter), the 3.5 kb NarI-BspEI fragment
from pPrPE i E23R (containing exons 1 and 2, the coding region of
exon 3 as well as intron 1) and the 3 kb Narl-SalI fragment of pNZW
BamnHI (comprising the 3' end of Prnp) were joined to Notl- and Sall-
cleaved, dephosphorylated pBluescript in a four-way ligation.
pPrPPEJ23RI. The 1.4 kb TfiI-EcoRI fragment of NMRI-cDNA (com-
prising exons 1. 2 and 3 up to the EcoRI site in the 3' non-coding
region), the 157 bp Tfil-BspEI fragment from pPrPS4 (comprising the
promoter sequences proximal to exon 1) and the 5.5 kb NotI-BspEI
fragment from cos6.IILNJ-4 (containing the promoter) were joined to
NotI- and EcoRI-digested. dephosphorylated pBluescript in a four-
way ligation.
pPrPcDNA. The 6 kb EcoRI fragment from pPrPPE123RI (part of the
promoter, exons and 2, the coding region of exon 3 as well as intron
1) was ligated to a dephosphorylated 6 kb EcoRI fragment from PrPHG
(comprising the plasmid backbone as well as promoter and 3 '-untranslated
sequences).
pPrPANco. pPrPHG was digested with NcoI and religated. Resulting
clones were screened for the presence and correct orientation of the
fragment comprising exon 1, and the absence of the small Ncol fragment
derived from exon 3.
pPrPAN-terni. A PCR product was prepared using pPrPHG as template,
primer prBspE5' (5 'caagcattaagccagtccggagcggtga3'). the mutation
primer prA32-80 (5'tccaccgccatggggttgcccccaccctccaggct3') and cloned
Pfui DNA polymerase (Stratagene). The 2 kb BspEI-NcoI fragment of
this PCR product (comprising exon 1, intron I and exon 3 up to the
deletion breakpoint) was joined to two fragments derived from pPrPHG,
the 9 kb BspEI-Sall fragment (comprising the vector backbone and the
PrP promoter) and the 3 kb NcoI-SalI fragment (comprising the 3' end
of the half-genomic gene).
pPrPAC-termtl. A PCR product was prepared using pPrPHG as template,
primer prBspe5' (5'caagcattaagccagtccggagcggtga3') and the mutation
primer prAC145 (5'cctccctcagtcgttgccaaaatggatcat3'). The 2.1 kb BspEI
fragment of this product (containing exon 1, intron 1, exon 2 and the
ORF of the mutated gene), the 9 kb BspEI-SalI (comprising the vector
backbone and the PrP promoter) and the 2.7 kb StuI-SalI fragment
(containing the 3' end of pPrPHG) of pPrPHG were joined in a three-
way ligation.
pPrPAN&C-term. All steps were carried out as for pPrPAC-term, except
that the template for PCR was pPrPAN-term rather than PrPHG.
Plasmid DNA from E.coli XLl-blue (Stratagene) was purified using
the Qiagen purification system. Linear amplification DNA sequencing
(PCR sequencing) was carried out essentially according to Adams and
Blakesly (1991).
Generation of transgenic mice
Plasmid DNA was digested with NotI and Sall (only with Notl in the
case of the cosmid), heated for 5 min at 65°C and electrophoresed
through a %lc agarose gel (Seakem GTG; FMC BioProducts, Denmark).
The PrP insert was purified using the Prep-A-Gene DNA extraction kit
(Bio-Rad, USA). diluted to 1-2 ng/,ul with TE buffer (10 mM Tris-HCI
pH 7.5. 0.5 mM EDTA), filtered through a Micropore filter (Millipore
Ultrafree MC 0.45 pm) pre-rinsed twice with TE buffer. Microinjection
into oocytes and re-implantation were as previously described (Brinster
et al., 1985; Wilmut et al., 1991).
PCR for the detection and quantitation of transgenes
Prnpo) and Prnp+ alleles, both transgenic and resident, were detected
and quantified by a modification of a previous protocol (Biueler et al.,
1992). One microlitre of either purified genomic DNA or crude tail
lysate (Laird et al., 1991) was added to 25 ,ul of PCR mix [50 mM KCI,
10 mM Tris-HCI (pH 9), 1.5 mM MgCl2, 2% deionized formamide,
0.1% bovine serum albumin (BSA), 0.1% Triton X-100, 0.5 ,uCi
[aX-32P]dATR 0.2 mM each of dATP, dCTP, dGTP, dTTP, 0.7 ,uM of
each primer and 0.6 units of Taq DNA polymerasel. Three primers were
used to detect transgenes simultaneously and, as internal standard, the
two Prnpo alleles P3 (specific for Prnpo) and PlO (specific for Prnp+)
(Bijeler et al., 1992) and prPrP3'nc (5'ataacccctcccccagcct3') (comple-
mentary to both Prnp+ and Prnpo). The primer prPrP3'nc is proximal
to the coding region of PrP, resulting in products of 350 bp for the
Prnp(-specific signal and 550 bp for the wild-type and N-terminal mutant
Prnp-specific signals. After 21 cycles in a thermal cycler (Perkin Elmer/
Cetus, USA; 45 s at 95°C, 45 s at 62°C and 1 min at 72°C) followed
by 7 min at 72°C and subsequent cooling to 4°C, 5 41 samples were
electrophoresed through agarose gels. After drying, the gels were
analyzed using a Phosphorlmager (Molecular Dynamics, USA). Copy
numbers were estimated by comparison with control reactions containing
appropriate cloned standards run in parallel.
Northern blots
Total brain RNA was prepared essentially as described (Chomczynski
and Sacchi, 1987) and electrophoresed through a 1%7 agarose gel. Pre-
hybridization and hybridization were according the Quikhyb protocol
(Stratagene). A 140 nucleotide single-stranded DNA probe was prepared
by linear amplification for 10 cycles of a NcoI-AvaII murine PrP cDNA
fragment comprising the sequence from codon 84 (His) to codon 145
(Glu), using a primer hybridizing to the DNA plus strand (pr del-:
5'tccccagcatgtagccaccaagg3'). The ,B-actin probe, an EcoRI-Hindlll
fragment of chicken f-actin cDNA (Cleveland et al., 1980), was 32p
labeled by the random primer method (Prime-It, Stratagene).
Western blot analysis
Electrophoresis of brain homogenates and blotting were carried out
essentially as described (BiUeler et al., 1994). The antibodies used were
R073, a rabbit polyclonal antiserum raised against PrP27-30 from
hamster (Serban et al., 1990), 1B3, a rabbit polyclonal serum directed
against SAF (aggregated PrP) from mouse (Farquhar et al., 1989) and
R3430. a rabbit polyclonal serum directed against the N-terminal peptide
PI from hamster PrP27-30 (GQGGGTHNQWNKP, identical to the
murine sequence comprising amino acids 89-102) (Barry et al.. 1986),
at a 1:2000 dilution.
Determination of PrPSC
Brain homogenates (10%7) in 0.32 M sucrose were adjusted to 0.5% in
SST buffer (20 mM Tris-HCI pH 7.5, 2% N-lauryl sodium sarcosine,
0.32 M sucrose) and further homogenized by drawing through a 26
gauge needle. Of this. 900 ,1u were digested with 5 4g/ml proteinase K
for 15 min at 370C. After adding 10 ,ul of 0.1 M phenylmethylsulfonyl
fluoride, 800 p1 were centrifuged at 100 000 g for 2 h at 10°C. The final
pellet was resuspended in 80 ,tl of SST and 40 ,d of 5X SDS loading
buffer containing I % mercaptoethanol and heated for 5 min in a
boiling waterbath.
Inoculations and scrapie diagnosis
Inocula were prepared by incubating cleared 10% brain homogenates
for 20 min at 80°C and subsequently diluting in phosphate-buffered
saline (PBS)-5%7 BSA. Mice were inoculated intracerebrally with 30 p1
of 1% brain extract, which was prepared from terminally scrapie-sick
mice (CD-I) inoculated with mouse-adapted (RML) prions as described
previously (Bueler et al., 1993). The animals were monitored at weekly
intervals for the first 40 days p.i. and at 2-day intervals thereafter.
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